Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? (Q38068534)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

0 references

Pilar Martinez Martinez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mario Losen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Alejandro M Gomez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Nick Willcox

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Peter C Molenaar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Wim Buurman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Marc H De Baets

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

20 February 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

1274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

48-59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Long-lasting treatment effect of rituximab in MuSK myasthenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Lifetime of plasma cells in the bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Humoral immunity due to long-lived plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Maintenance of the plasma cell pool is independent of memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Protective immunity remains intact after antibody removal by means of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Proteasome inhibitor treatment of antibody-mediated allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Therapeutic inhibition of proteasomes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Immunosuppressive therapies in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Discovery and development of second-generation proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06824.X

10.1111/J.1749-6632.2012.06824.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23252897%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference